Reproductive factors, menopausal hormone therapy, and risk of non-Hodgkin, diffuse large B-cell and follicular lymphomas: a UK case–control study
- 135 Downloads
Most non-Hodgkin lymphoma (NHL) subtypes occur more among men than women. Since sex hormones may influence immune function, female hormones may be involved. To investigate the relationship between NHL subtypes and reproductive factors, findings from a UK population-based case–control study (1998–2003) are presented.
Female cases (n = 389) and controls (n = 394) aged 16–69 reported their reproductive histories. Odds ratios (ORs) and 95% confidence intervals (CI) were computed using unconditional logistic regression.
No associations were found for age at menarche, parity, or age at first child. Among postmenopausal women, hormone therapy (HT) users had risks of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) below one compared to non-users (OR = 0.7, 95% CI 0.5,1.2; OR = 0.6, 95% CI 0.4,1.0, respectively). Estimates agree with other reports: meta-analyses gave pooled ORs of 0.8 (95% CI 0.6,0.9) for DLBCL and 1.0 (95% CI 0.8,1.2) for FL. In our study, ORs decreased with years of HT use: less and more than 5 years being 0.9 (95% CI 0.5,1.5) and 0.6 (95% CI 0.3,1.1) for DLBCL (p-trend = 0.22), and 0.8 (95% CI 0.4,1.4) and 0.4 (95% CI 0.2,0.9) for FL (p-trend = 0.06).
For greater power to investigate the association of hormones with DLBCL, FL, and rarer NHL subtypes, pooling data through the International Lymphoma Epidemiology Consortium (InterLymph) is warranted.
KeywordsCase–control study Menopausal hormone therapy Lymphoma, Non-Hodgkin Meta-analysis Reproductive history
We thank Professor Andrew Jack, Dr Bridget Wilkins and Dr Sharon Barrans for reviewing the diagnoses.
Conflict of interest
The EGU Lymphoma Case–Control Study is supported by Leukaemia & Lymphoma Research, UK. Katherine Mildon is supported by the UK Medical Research Council (MRC).
- 3.IARC Working Group on the Evaluation of Carcinogenic Risks to Humans (1999) Hormonal contraception and post-menopausal hormonal therapy. International Agency for Research on Cancer, Lyon, FranceGoogle Scholar
- 24.World Health Organization (2000) International Classification of Disease for Oncology, 3rd edn. World Health Organisation, GenevaGoogle Scholar
- 26.Million Women Study Collaborators (2002) Patterns of use of hormone replacement therapy in one million women in Britain, 1996–2000. BJOG 109(12):1319–1330Google Scholar